carbamates has been researched along with Brain Vascular Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Su, SH | 1 |
| Wu, YF | 1 |
| Lin, Q | 2 |
| Hai, J | 2 |
| Wang, D | 1 |
| Su, S | 1 |
| Liu, K | 1 |
| Wu, Y | 1 |
| SANCHETTI, P | 1 |
| FAVERO, S | 1 |
| Erkinjuntti, T | 1 |
| Román, G | 1 |
| Gauthier, S | 1 |
| Feldman, H | 1 |
| Rockwood, K | 1 |
| Abrányi, I | 1 |
1 review available for carbamates and Brain Vascular Disorders
| Article | Year |
|---|---|
[Contribution of angioxine to the vascular protection of the diabetic].
Topics: Animals; Carbamates; Cerebrovascular Disorders; Coronary Disease; Diabetic Angiopathies; Diabetic Re | 1976 |
1 trial available for carbamates and Brain Vascular Disorders
| Article | Year |
|---|---|
The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
Topics: Aged; Carbamates; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Humans; Male; Middle | 1976 |
4 other studies available for carbamates and Brain Vascular Disorders
| Article | Year |
|---|---|
Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 ameliorate neuroinflammatory responses in chronic cerebral hypoperfusion model by blocking NF-κB pathways.
Topics: Amidohydrolases; Animals; Anti-Inflammatory Agents; Benzamides; Benzoxazines; Cannabinoid Receptor A | 2017 |
URB597 improves cognitive impairment induced by chronic cerebral hypoperfusion by inhibiting mTOR-dependent autophagy.
Topics: Amidohydrolases; Animals; Apoptosis; Autophagy; Benzamides; CA1 Region, Hippocampal; Carbamates; Car | 2017 |
[CLINICAL STUDY OF A NEW COMPLEX HYPOTENSIVE DRUG COMBINATION].
Topics: Antihypertensive Agents; Arteriosclerosis; Carbamates; Cerebrovascular Disorders; Coronary Disease; | 1963 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition | 2004 |